BioSignia

BioSignia is a health technology company specializing in advanced clinical predictive modeling for chronic disease risk assessment. The company's proprietary Synthesis platform integrates multiple clinical and lifestyle data points to provide personalized risk scores for conditions such as cardiovascular disease and type 2 diabetes. By utilizing a systems biology approach, BioSignia aims to shift healthcare from reactive treatment to proactive prevention. Their tools are primarily used by healthcare providers, insurers, and clinical laboratories to improve patient outcomes through early intervention. In 2013, BioSignia was acquired by LabCorp to bolster its diagnostic and personalized medicine capabilities.